Blood/Plasma Collection Device For Dna Testing

What the Data Shows About Blood/Plasma Collection Device For Dna Testing

The FDA MAUDE database aggregates 576 adverse-event reports for Blood/Plasma Collection Device For Dna Testing spanning the period from 2018 through 2026. Of these, 0 are classified as death reports, 0 as injury reports, and 576 as malfunction reports under FDA adverse-event categorization rules. Report counts do not by themselves indicate a device is unsafe — widely used devices and longer market histories naturally generate larger raw counts, so proportional and comparative reads are more informative than totals alone.

The adverse-event profile breaks down across 1 distinct event type and 2 reported patient-outcome categories, giving a multi-dimensional view that goes beyond a single headline number. A total of 20 distinct product-problem codes appear in the reports, with Incorrect, Inadequate or Imprecise Result or Readings topping the list at 250 reports. Reports are associated with 8 different manufacturers in the MAUDE record, reflecting both OEMs and repackagers of this device category.

Annual reporting volume is tracked across 9 years of MAUDE data, with the peak single-year volume reaching 264 reports — trend shape often reflects changes in device adoption, reporting rules, or FDA enforcement focus rather than underlying device behavior alone. Events are documented across 2 reported care-setting categories (hospital, home, ambulatory surgery center, etc.). All figures reflect the openFDA MAUDE snapshot last refreshed on 2026-05-15. This page is informational and is not medical advice — discuss device-safety questions with your healthcare provider.